• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 29
  • 22
  • 11
  • 4
  • 4
  • 3
  • 1
  • 1
  • Tagged with
  • 79
  • 55
  • 28
  • 21
  • 17
  • 13
  • 9
  • 8
  • 7
  • 7
  • 7
  • 6
  • 6
  • 6
  • 6
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
31

Protéine kinase GCN2 et phosphorylation de l’intégrase du VIH-1 / Kinase GCN2 and the phosphorylation of HIV-1 integrase

Jaspart, Anaïs 12 December 2014 (has links)
L’intégrase (IN) du VIH-1 est une enzyme clé qui catalyse l’insertion stable du génome viral dans celui de la celluleinfectée. D’autre part, l’IN participe également à de nombreuses étapes du cycle viral telles que la transcriptioninverse ou la maturation virale. La compréhension des mécanismes impliqués dans la régulation de l’intégrationcellulaire au cours de l’infection est un enjeu important. L’IN fait partie du complexe de préintégration composé defacteurs cellulaires et viraux. La dynamique des interactions au sein de ce complexe régule les activités catalytiquesmais également non catalytiques de l’IN. C’est dans ce contexte de recherche de nouveaux cofacteurs de l’intégraseque nous avons identifié une interaction entre l’IN et la protéine Kinase GCN2.Mon travail de thèse s’est orienté sur trois questions autour de l’étude du rôle de cette interaction IN/GCN2.- Dans un premier temps, le rôle de la protéine kinase cellulaire GCN2 au cours du cycle viral a été étudié. Nousavons pu montrer que l’infection par le VIH-1 provoque un stress activant GCN2. Cette activation aboutit à uneinhibition de la traduction dès les premières heures de l’infection.- GCN2 est capable de phosphoryler l’IN du VIH-1 sur deux positions : les sérines en position 24 et 255. L’étude durôle de la phosphorylation de l’IN par GCN2 a permis de montrer que l’absence de phosphorylation de l’IN entraîneune stimulation de l’infection. GCN2 via la phosphorylation de l’IN a donc un effet restrictif sur l’infection par le VIH-1.- L’étude du domaine d’interaction entre l’IN et GCN2 a permis d’identifier un résidu essentiel de l’IN, l’acideglutamique en position 85 (E85). En effet, la mutation E85A de l’IN entraîne la production de virus non infectieux,suite à un défaut de maturation / HIV-1 integrase (IN) catalyzes the integration of the viral DNA into the cellular genome. Besides, IN is also involved inother steps of the viral life cycle like the reverse transcription or the viral maturation. Our group is interested in themechanisms involved in the regulation of cellular integration during the infection. IN is part of a pre-integrationcomplex composed of cellular and viral proteins. The dynamic of these interactions regulates IN activities but also noncatalytic activities such as nuclear import and tethering of the complex to the integration site. During theidentification of news partners of IN, an interaction between IN and the kinase GCN2 was characterizedMy PhD project is composed of 3 topics:- The role of the cellular kinase GCN2 was studied during the viral cycle. We showed that GCN2 is activated uponHIV-1 infection. This activation leads to a general decrease of cellular translation during the first hours of infection.-GCN2 is able to phosphorylate IN on two positions: the serines in position 24 and 255. The absence of INphosphorylation causes a stimulation of HIV-1 infection. We demonstrate that GCN2 affects the viral cycle via thephosphorylation of IN.- Binding domain analysis between IN and GCN2 led to the identification of a critical residue of IN, the glutamicacid in position 85 (E85). Mutations E85A of IN impair the viral production by inhibiting the viral maturation.
32

Mechanism of action of allosteric HIV-1 integrase inhibitors

Slaughter, Alison Paige 22 May 2015 (has links)
No description available.
33

Structures et fonctions du domaine C-Terminal de l'intégrase du VIH-1 / Structures and functions of the C-Terminal domain of HIV-1 integration

Oladosu, Oyindamola 16 May 2017 (has links)
L’Integrase du VIH est une ADN recombinase catalysant deux réactions qui permettent l'intégration de l'ADN viral dans l'ADN hôte. L’intégrase du VIH comprend 3 domaines : N-terminal impliqué dans la réaction de « 3' processing » et le transfert de brin, le domaine catalytique contenant le site actif et le domaine C-terminal liant l'ADN non-spécifiquement (CTD). Des recherches récentes mettent en évidence l'importance du CTD dans la liaison avec d'autres protéines virales comme la transcriptase inverse. Le but de la thèse était de comprendre les rôles et l'importance du domaine C-terminal de l’intégrase dans deux contextes : l'intégration dans la chromatine et la coévolution, avec l'objectif de comprendre le rôle de la multimerisation dans la fonction de l’intégrase. Globalement, les résultats de mon projet indiquent que l'IN-CTD joue un rôle important, en contribuant à la formation de multimères d'ordre supérieur importants pour la fonction de l’IN. / HIV Integrase is a DNA recombinase that catalyzes two endonucleolytic reactions that allow the viral DNA integration into host DNA for replication and subsequent viral protein production. HIV Integrase consists of 3 structural and functional domains: The N-terminal zinc domain involved in 3’ processing and strand transfer, the catalytic core domain which contains the active site, and the C-terminal domain that binds DNA non- specifically. Recent research highlights the importance of the CTD in binding with other viral proteins such as Reverse Transcriptase. The aim of the thesis was to understand the roles and importance of the C-terminal domain of HIV-1 Integrase in two contexts: chromatin integration, and co-evolution, with the overall purpose of understanding the role of multimerization in IN function. Overall, results from my project indicate that the IN-CTD plays an important role, by contributing to the formation of higher order multimers that are important for IN functionality.
34

Análise da diversidade genética e mutações no gene da integrase de isolados do HIV-1 de pacientes atendidos no município de Jataí/Goiás / Analysis of genetic diversity and mutations in the gene of the HIV-1 isolate integration of patients served in the municipality of Jataí / Goiás

Paula, Marcella Silva de 11 April 2018 (has links)
Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2018-05-14T13:06:07Z No. of bitstreams: 2 Dissertação - Marcella Silva de Paula - 2018.pdf: 2802750 bytes, checksum: 99659e0beca35484a0765a68de6bfdd7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-05-14T13:08:05Z (GMT) No. of bitstreams: 2 Dissertação - Marcella Silva de Paula - 2018.pdf: 2802750 bytes, checksum: 99659e0beca35484a0765a68de6bfdd7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-05-14T13:08:05Z (GMT). No. of bitstreams: 2 Dissertação - Marcella Silva de Paula - 2018.pdf: 2802750 bytes, checksum: 99659e0beca35484a0765a68de6bfdd7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-04-11 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / INI have been available in Brazil since 2009, when the first INI, Raltegravir, became available for therapy of rescue of HIV + patients in therapeutic failure. In the year 2017, a second INI was introduced into ART of patients newly diagnosed with HIV-1, Dolutegravir, which had a higher genetic barrier and a single daily dose, replaced Efavirenz in the first line of treatment. However, despite the efficiency of INI, the emergence of viral variants resistant to these drugs is inevitable. For this reason, it is necessary to monitor resistance mutations to INI, which may lead to therapeutic failure, aiming at optimizing the therapeutic regimen and controlling HIV infection. The objective of this study was to evaluate the occurrence of INI mutations and the resistance profile in HIV + / AIDS patients in the city of Jataí/Goiás. The complete IN gene was sequenced from samples from INI-naive patients. Resistance mutations were identified by the Stanford-HIV and IAS-USA database. Viral subtypes were identified by phylogenetic analysis. Among the 52 samples analyzed, no primary mutation was identified. Two accessory mutations (T97A / G163K) were identified and these induce a low level of INI resistance. In total, 152 polymorphisms were identified. The most prevalent subtype was subtype B. Therefore, these data demonstrate that the IN region is still highly conserved, encouraging the use of INI in HIV-1 therapy, and assist in the mapping of HIV-1 genetic diversity in the Southwest region of Goiás. / Os INI estão disponíveis no Brasil desde 2009, quando o primeiro INI, Raltegravir, passou a ser disponibilizado para terapia de resgate de paciente HIV+ em falha terapêutica. No ano de 2017, umsegundo INI foi introduzido na TARV de pacientes recém diagnosticados com HIV-1, o Dolutegravir, que por possuir barreira genética mais elevada e dose diária única, substituiu o Efavirenz na primeira linha de tratamento. Porém, apesar da eficiência dos INI, a emergência de variantes virais resistentes a estes fármacos é inevitável. Por isto, é necessário o monitoramento das mutações de resistência aos INI, que podem levar falha terapêutica, visando a otimização do esquema terapêutico e controle da infecção pelo HIV. O objetivo deste estudo foi avaliar a ocorrência de mutações aos INI e o perfil de resistência em pacientes HIV+/AIDS do município de Jataí/Goiás. O gene completo da IN foi sequenciado a partir de amostras de pacientes virgens de INI. As mutações de resistência foram identificadas pelo banco de dados de Stanford-HIV e IAS-USA. Os subtipos virais foram identificados por análise filogenética. Entre as 52 amostras analisadas, nenhuma mutação primária foi identificada. Duas mutações acessórias (T97A/G163K) foram identificadas e estas induzem baixo nível de resistência à Raltegravir e Elvitegravir. No total, 152 polimorfismos foram identificados. O subtipo mais prevalente foi o subtipo B. Portanto, estes dados demonstram que a região da IN ainda é bastante conservada, encorajando o uso de INI na terapia contra o HIV-1 e auxiliam no mapeamento da diversidade genética do HIV-1 na região Sudoeste Goiano
35

Développement d'inhibiteurs de la dimérisation du complexe de la Reverse Transcription du VIH-1 / Dimerization of HIV-1 Reverse Transcriptase as a potent target to block HIV replication

Moustapha Abba Moussa, Daouda 07 June 2013 (has links)
Le virus de l'immunodéficience humain de type 1 VIH-1 est un rétrovirus responsable d'une pandémie touchant actuellement 34 millions de personnes dont près de 25 millons en sont morts. En dépit des grands progrès réalisés dans le développement de nouveaux médicaments visant à bloquer la réplication de ce virus, l'émergence rapide de souches virales mutantes résistantes imposent l'urgence et la nécessité de développer de nouvelles stratégies thérapeutiques pour combattre ce virus. La Reverse Transcriptase (RT) duVIH-1 joue un rôle majeur dans le cycle viral puisqu'elle est responsable de convertir l'ARN génomique simple brin en ADN double afin d'intégrer l'ADN génomique de la cellule hôte. La forme biologique de la RT est un hétérodimère formé de la sous unité p66 et la sous unité p51. Les sous unités sont constituées des sous domaines fingers, palm, « connection », thumb et RNase H, ce dernier étant absent sur la sous unité p51. L'activation de la RT est un processus en deux étapes : la première étape consiste en l'association rapide des deux sous unités, suivie d'une deuxième étape plus lente, correspondant à des changements conformationnels fins à l'interface entre p66/p51.Dans l'objectif d'inhiber la fonction de la RT, nous avons proposé une nouvelle stratégie fondée sur l'utilisation des peptides interfacials courts dérivant de séquences hautement conserver de la RT, capables de cibler efficacement les interactions protéine/protéine et de bloquer la dimérisation et l'activation par maturation de la RT. La dimérisation des deux sous unités implique leur interaction part les domaines de connexion. Dans la première partie de ce travail de thèse, nous avons criblé et isolé des peptides capables d'interférer avec cette interaction impliquant un « cluster » de résidus aromatiques. Nous avons identifié un peptide court PID4, et démontré que ce peptide induit un changement de conformation de la RT, entrainant la dissociation du complexe. La maturation implique l'interaction de résidus localisés au niveau de « hot spot » dans le domaine RNase H de p66 et thumb de p51. Dans la deuxième partie de cette thèse, nous avons sélectionné un peptide court, P27, issus du domaine thumb pouvant inhiber l'étape de la « maturation » (P27). Ces deux classes de peptides bloquent la réplication virale et sont efficaces sur plusieurs souches virales et sur des mutants résistants aux NNRTIS et NRTIS.Les résultats obtenus sur nos deux classes d'inhibiteurs peptidiques, démontrent bien que la dimérisation et la maturation de la RT constituent des cibles de choix pour bloquer l'activité polymérase de la RT et ainsi stopper la prolifération virale par un nouvel concept moins exposer à l'émergence des mutation de résistance. / The human immunodeficiency virus type 1 (HIV-1) is a retrovirus responsible of a disease currently affecting 34 million people and caused the death of 25 million people from its discovery in the 1980s. Despite the great progresses made in the development of new drugs to block the replication of the virus, the rapid emergence of resistant mutant strains requires the development of new therapeutic strategies to combat this agent.The Reverse transcriptase (RT) plays an essential role in the replication of human immunodeficiency virus type 1 (HIV-1) and remains a primary target of anti-HIV-1 drugs. The biologically active form of HIV-1 RT is a heterodimer of two subunits, p51 and p66, each consisting of distinct sub-domains: the fingers, the palm, the connection and the thumb are present in both of them. p66 contain also an RNAse H sub-domains. The formation of RT is a two-step mechanism, involving first the rapid association of the two subunits (Dimerization), followed by conformational changes (Maturation) yielding the biologically active form of the enzyme.In order to inhibit the function of RT, we have proposed and elaborated a new strategy based on short interfacial peptides that target protein-protein interfaces involved in RT- dimerization and activation. The dimerization of two subunits involves interaction between their connection domains. In the first part of this thesis, we screened and isolated peptides capable of interfering with the interaction, involving a "cluster" of aromatic residues. We identified a short peptide PID4, and demonstrated that induces a conformational change in the RT, resulting in dissociation of the heterodimer complex. Maturation involves the interaction of residues located at "hot spot" in the RNase H domain of p66 and the thumb domain of p51. The second part of this thesis is based on a screening of peptides, derived from the thumb domain of the enzyme. We have identified a short peptide (P27) which inhibits the maturation step and abolish replication of HIV-1 LAI. These two classes of peptides block viral replication and are effective in several viral strains and mutants resistant to NNRTIs and NRTIs.Taken together, the results of our two classes of peptides inhibitors, demonstrate that the dimerization and maturation of RT constitutes an attractive target for AIDS chemotherapeutics and for the design of more specific new antiviral drugs that can bypass resistance limitation.
36

Modelagem molecular de uma série de compostos inibidores da enzima integrase do vírus HIV-1 / Molecular modelling for a series of integrase HIV-I inhibitors

Carvalho, Luciana Luzia de 20 July 2011 (has links)
Uma etapa essencial no ciclo de vida do vírus HIV é a integração do DNA viral no cromossomo hospedeiro. Essa etapa é catalisada pela enzima integrase (IN) de 32-kDa. HIV-1 IN é um importante e validado alvo, e as drogas que inibem seletivamente a enzima, quando utilizadas em combinação com os inibidores da transcriptase reversa (RT) e protease (PR), são consideradas altamente eficazes em suprimir a replicação viral. IN catalisa dois processos enzimáticos designados por 3\' processamento e transferência de DNA. Agentes ativos contra integrase, inibindo a etapa de transferência da vertente já estão em fase clínica. O fármaco Raltegravir® é o primeiro nesta nova classe. Os ensaios clínicos no tratamento em novos pacientes têm uma atividade anti-retroviral potente e bem tolerado. Dada a sua potência, segurança e novo mecanismo de ação, os inibidores da integrase representam um importante avanço terapêutico contra o HIV-1. Na presente tese de doutorado, foram realizados estudos quimiométricos utilizando descritores teóricos e QSAR bi- (2D) e tridimensionais (3D) empregando, respectivamente, as técnicas holograma QSAR (HQSAR) e a análise comparativa dos campos moleculares (CoMFA), visando à geração de modelos preditivos para um conjunto de inibidores da integrase do vírus HIV-1. Modelos de QSAR com boa consistência interna, habilidade preditiva e estabilidade foram obtidos em todos os casos. Os modelos gerados, associados às informações obtidas pelos mapas de contribuição 2D e de contorno 3D, são guias químico-medicinais úteis no planejamento de novos inibidores mais potentes e seletivos da integrase do HIV-1. / An essential step in the HIV life cycle is integration of the viral DNA into the host chromosome. This step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN). HIV-1 IN is an important and validated target, and the drugs that selectively inhibit this enzyme, when used in combination with reverse transcriptase (RT) and protease (PR) inhibitors, are believed to be highly effective in suppressing the viral replication. IN catalyzes two discrete enzymatic processes referred as 3\' processing and DNA strand transfer. Agents active against HIV-1, which target the viral integrase by inhibiting the strand transfer step of integration, have now initialized the clinical trials. The Raltegravir® is the first drug in this new class. Clinical trials in treatment-experienced and in treatment-naive patients have shown that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated. Given their potency, safety and novel mechanism of action, integrase inhibitors represent an important advance in HIV-1 therapy. In the present thesis, Bi- and Tridimensional Quantitative Structure-Activity Relationship (QSAR) studies were performed applying chemometric methods based on theoretical descriptors, Comparative Molecular Field Analysis (CoMFA) and Holograma QSAR (HQSAR) techniques, aiming to generate predictive models for a large set of HIV-1 IN inhibitors. QSAR models presenting good internal consistency, predictive power and stability were obtained in all cases. The final models along with the information resulted by 2D contribution and 3D contour maps should be useful in the design of new inhibitors with increased potency and selective within the chemical diversity of the data.
37

Modelagem molecular de uma série de compostos inibidores da enzima integrase do vírus HIV-1 / Molecular modelling for a series of integrase HIV-I inhibitors

Luciana Luzia de Carvalho 20 July 2011 (has links)
Uma etapa essencial no ciclo de vida do vírus HIV é a integração do DNA viral no cromossomo hospedeiro. Essa etapa é catalisada pela enzima integrase (IN) de 32-kDa. HIV-1 IN é um importante e validado alvo, e as drogas que inibem seletivamente a enzima, quando utilizadas em combinação com os inibidores da transcriptase reversa (RT) e protease (PR), são consideradas altamente eficazes em suprimir a replicação viral. IN catalisa dois processos enzimáticos designados por 3\' processamento e transferência de DNA. Agentes ativos contra integrase, inibindo a etapa de transferência da vertente já estão em fase clínica. O fármaco Raltegravir® é o primeiro nesta nova classe. Os ensaios clínicos no tratamento em novos pacientes têm uma atividade anti-retroviral potente e bem tolerado. Dada a sua potência, segurança e novo mecanismo de ação, os inibidores da integrase representam um importante avanço terapêutico contra o HIV-1. Na presente tese de doutorado, foram realizados estudos quimiométricos utilizando descritores teóricos e QSAR bi- (2D) e tridimensionais (3D) empregando, respectivamente, as técnicas holograma QSAR (HQSAR) e a análise comparativa dos campos moleculares (CoMFA), visando à geração de modelos preditivos para um conjunto de inibidores da integrase do vírus HIV-1. Modelos de QSAR com boa consistência interna, habilidade preditiva e estabilidade foram obtidos em todos os casos. Os modelos gerados, associados às informações obtidas pelos mapas de contribuição 2D e de contorno 3D, são guias químico-medicinais úteis no planejamento de novos inibidores mais potentes e seletivos da integrase do HIV-1. / An essential step in the HIV life cycle is integration of the viral DNA into the host chromosome. This step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN). HIV-1 IN is an important and validated target, and the drugs that selectively inhibit this enzyme, when used in combination with reverse transcriptase (RT) and protease (PR) inhibitors, are believed to be highly effective in suppressing the viral replication. IN catalyzes two discrete enzymatic processes referred as 3\' processing and DNA strand transfer. Agents active against HIV-1, which target the viral integrase by inhibiting the strand transfer step of integration, have now initialized the clinical trials. The Raltegravir® is the first drug in this new class. Clinical trials in treatment-experienced and in treatment-naive patients have shown that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated. Given their potency, safety and novel mechanism of action, integrase inhibitors represent an important advance in HIV-1 therapy. In the present thesis, Bi- and Tridimensional Quantitative Structure-Activity Relationship (QSAR) studies were performed applying chemometric methods based on theoretical descriptors, Comparative Molecular Field Analysis (CoMFA) and Holograma QSAR (HQSAR) techniques, aiming to generate predictive models for a large set of HIV-1 IN inhibitors. QSAR models presenting good internal consistency, predictive power and stability were obtained in all cases. The final models along with the information resulted by 2D contribution and 3D contour maps should be useful in the design of new inhibitors with increased potency and selective within the chemical diversity of the data.
38

Síntese de candidatos a novos inibidores da enzima Hiv-integrase

Rezende Júnior, Celso de Oliveira 30 July 2010 (has links)
Submitted by isabela.moljf@hotmail.com (isabela.moljf@hotmail.com) on 2017-05-05T14:14:07Z No. of bitstreams: 1 celsodeoliveirarezendejunior.pdf: 1703037 bytes, checksum: 06b6ddaff72097b07ba5ec7185f315b5 (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-05-17T13:40:18Z (GMT) No. of bitstreams: 1 celsodeoliveirarezendejunior.pdf: 1703037 bytes, checksum: 06b6ddaff72097b07ba5ec7185f315b5 (MD5) / Made available in DSpace on 2017-05-17T13:40:18Z (GMT). No. of bitstreams: 1 celsodeoliveirarezendejunior.pdf: 1703037 bytes, checksum: 06b6ddaff72097b07ba5ec7185f315b5 (MD5) Previous issue date: 2010-07-30 / CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico / Este trabalho trata da síntese de cicloexanopoliois derivados do ácido quínico, esterificados com os ácidos cafeico e gálico. Esses compostos são candidatos novos agentes antivirais, principalmente como inibidores da enzima HIV-integrase, devido à semelhança estrutural com os derivados dicafeoíl-cicloexanodiois e ácidos dicafeoíl-quínicos, potentes inibidores dessa enzima. A partir de reações de esterificação, proteção e desproteção de compostos fenólicos e cicloexanopoliois foram sintetizados 41 compostos, sendo 26 inéditos, com rendimentos que variaram de 20 a 100%. As reações de proteção e desproteção seletivas das hidroxilas foram realizadas com sucesso. Na benzilação dos compostos (1R,2S,3R,5S)-1,2-Ocicloexilideno-1,2,3,5-tetraidroxicicloexano e (1R,2S,3R,5R)-1,2-O-cicloexilideno- 1,2,3,5-tetraidroxicicloexano a metodologia por transferência de fase se mostrou mais eficiente do que a metodologia convencional. Na tentativa de clivagem seletiva dos grupos benzila dos compostos (1R,2S,3R,5S)-1,2-di-O-(3’,4’-di-O-acetil)-cafeoíl-3,5-di-O-benzil-1,2,3,5-tetraidroxicicloexano e (1R,2S,3R,5R)-1,2-di-O-(3’,4’-di-Oacetil)-cafeoíl-3,5-di-O-benzil-1,2,3,5-tetraidroxicicloexano foram utilizadas quatro metodologias diferentes obtendo-se, para cada uma, a clivagem de grupos protetores diferentes. As estruturas dos compostos obtidos foram elucidadas por espectroscopia na região do infravermelho, RMN de 1H e de 13C, além da caracterização por ponto de fusão e poder rotatório específico. Alguns compostos finais foram encaminhados para testes anti-herpes (HSV-1 e HSV-2) e para avaliação das propriedades antioxidantes e antiparasitárias e serão encaminhados para testes anti- HIV-integrase. / This work describes the synthesis of cyclohexanepoliols derived from quinic acid, esterified with caffeic and gallic acids. These compounds are candidates as new antiviral agents, particularly as inhibitors of HIV integrase, due to their structural similarity to dicaffeoyl cyclohexanediols and dicaffeoyl quinic acid derivatives, potent inhibitors of this enzyme. We synthesized 41 compounds using reactions of esterification, protection and deprotection of phenolic and cyclohexanepoliol derivatives. The reactions of protection and selective deprotection of the hydroxyl groups were performed successfully. In the benzylation of compounds (1R, 2S, 3R, 5S)-1,2-O-cyclohexylidene-1,2,3,5-tetrahydroxycyclohexane and (1R, 2S, 3R, 5R)-1,2-O-cyclohexylidene-1,2,3,5-tetrahydroxycyclohexane the methodology employing phase transfer was more efficient than the conventional method. In an attempt to cleave selectively the benzyl groups of compounds (1R, 2S, 3R, 5S)-1,2-di-O-(3',4'-di-O-acetyl)-caffeoyl-3,5-di-O-benzyl-1,2,3,5-tetrahydroxycyclohexane and (1R,2S,3R,5R)-1,2-di-O-(3',4'-di-O-acetyl)-caffeoyl-3,5-di-O-benzyl-1,2,3,5- tetrahydroxycyclo-hexane four different methodologies were used. Each procedure led to cleavage of different protecting groups. The structures of the compounds were characterized by infrared spectroscopy, 1H and 13C NMR, melting point and specific optical rotation. Final compounds were sent for testing against herpes (HSV-1 and HSV-2) and biological evaluation of their antiparasitic and antioxidant properties and will be referred for testing against HIV integrase.
39

Untersuchungen zum Aufbau, zur Funktion und zur Verbreitung von genomischen Inseln in der Gattung Legionella

Lautner, Monika 25 February 2013 (has links)
Der Austausch von genetischem Material über horizontalen Gentransfer, stellt einen wichtigen Mechanismus in der bakteriellen Evolution dar. Legionella pneumophila Stämme codieren für verschiedene Typ IV Sekretionssysteme (T4SS) und integrative konjugative Elemente, die zur genomischen Variabilität der intrazellulären Erreger beitragen. L. pneumophila Corby codiert auf der genomischen Insel Trb-1 für ein funktionelles Konjugations- und T4ASS. Trb-1 ist innerhalb des tRNAPro Gens integriert und kann in einer chromosomalen oder zirkulären episomalen Form existieren. Zusätzlich zu den trb/tra Genen sind auf der Insel eine Integrase (int-1) und die Gene lvrRABC der Legionella vir Region (lvr) lokalisiert. Durch die Deletion von int-1 konnte gezeigt werden, dass die Exzision von Trb-1 unter Beteiligung der Integrase erfolgt. Zudem wurde in dieser Arbeit zum ersten Mal demonstriert, dass die lvr-Region, vor allem der putative Phagen-Repressor LvrR an der Regulation der Exzision von Trb-1 beteiligt ist. Die Konjugation von Trb-1 in L. oakridgensis, hatte keinen Effekt auf die in vivo Fitness der Transkonjuganten in humanen Makrophagen. Die genomischen Inseln LpcGI-1 und LpcGI-2 codieren für ein neues putatives GI-T4SS. Für LpcGI-2 konnte erstmals gezeigt werden, dass das T4SS funktionell ist und die Konjugation der genomischen Insel in einen anderen L. pneumophila Stamm vermitteln kann. LpcGI-2 kann anschließend ortsspezifisch in das Genom der Transkonjuganten integriert werden. LpcGI-1 und LpcGI-2 werden vom tRNAThr bzw. tRNAMet Gen flankiert und können in verschiedenen chromosomalen und zirkulären, episomalen Formen existieren. Die Exzision von LpcGI-2 erfolgt ähnlich zu Trb-1, in Abhängigkeit einer ortsspezifischen Integrase. Im Genom von Lp Corby wurden zwei weitere genomische Inseln (LpcGI-Asn und LpcGI-Phe) identifiziert. In silico Analysen zeigten zudem, dass genomische Inseln mit einer Ähnlichkeit zu Trb-1, LpcGI-2 bzw. LpcGI-1 im Genus Legionella verbreitet sind. / Exchange of genetic information by horizontal gene transfer is an important mechanism for the evolution of bacterial genomes. Legionella pneumophila strains encode different type IV secretion systems and integrative conjugative elements contribute to the variability of the intracellular pathogen. The genomic island Trb-1 of L. pneumophila Corby encodes a functional conjugation and T4ASS. Trb-1 is integrated within the tRNAPro gene and can exist in a chromosomal or an episomal circular form. In addition to the trb/tra genes, a site-specific integrase (int-1) and a Legionella vir region (lvrRABC) are also localized on the genomic island. By deleting the int-1 gene, it could be demonstrated that the excision and of Trb-1 is integrase dependent. Furthermore, in this work it was shown for the first time that the lvr region and especially the putative phage repressor LvrR, is involved in the regulation of Trb-1 excision. Conjugation of Trb-1 in L. oakridgensis does not influence the in vivo fitness of the transconjugants in human macrophages. The genomic islands LpcGI-1 and LpcGI-2 encode a new putative T4SS. For the first time it could be demonstrated, that the T4SS localized on LpcGI-2 is functional. Although LpcGI-2 could be mobilized and transferred via conjugation to another L. pneumophila strain, followed by the site-specific integration into the genome of the transconjugants. LpcGI-1 and LpcGI-2 are flanked by the tRNAThr or tRNAMet gene respectively. Both islands can exist in different chromosomal and episomal forms. The excision of LpcGI-2 occurs similar to Trb-1 in an integrase dependent manner. Two additional genomic islands (LpcGI-Asn and LpcGI-Phe) could be identified in the genome of Lp Corby. Moreover, data of the in silico analysis demonstrated, that genomic islands similar to Trb-1, LpcGI-2 and LpcGI-1 are distributed within the genus Legionella.
40

Régulation de l'intégration du VIH-1 par la protéine TOX4, la transcription et la topologie de l'ADN cellulaire / Regulation of HIV-1 integration by TOX4 protein, transcription and topology of cellular DNA

Xavier, Johan 16 July 2014 (has links)
L’intégration de la copie ADN du VIH-1 dans le génome d’une cellule infectée est une étape essentielle du cycle réplicatif de ce rétrovirus. Elle est réalisée par une enzyme virale, l’intégrase, qui constitue une cible privilégiée des stratégies antivirales. Différentes études suggèrent une régulation de la sélectivité d’intégration par la chromatine et la transcription. La protéine cellulaire LEDGF/p75, activateur transcriptionnel, interagissant à la fois avec l’intégrase et la chromatine constitue une parfaite illustration de cette régulation.Mon projet de thèse a été d’étudier les liens entre LEDGF/p75, la chromatine et la transcription au cours de l’intégration du VIH-1.Tout d’abord, mes travaux ont permis de valider in vitro l’interaction entre LEDGF/p75 et son partenaire TOX4, récemment identifié par notre équipe. J’ai également montré que le domaine de TOX4, fixant LEDGF/p75, inhibe in vitro l’intégration sur matrice chromatine en présence de LEDGF/p75, suggérant un rôle inhibiteur de TOX4 à l’étape d’intégration du VIH-1.Ensuite, j’ai mis au point des protocoles in vitro de couplage entre l’intégration et la transcription. L’utilisation d’extraits nucléaires pour transcrire par l’ARN polymérase II n’étant pas compatible avec le processus d’intégration, j’ai utilisé l’ARN polymérase T7 purifiée comme machinerie de transcription et étudié les conséquences sur l’intégration. Bien que l’ARN synthétisé inhibe l’intégration, j’ai pu montrer que le passage d’une ARN polymérase sur la matrice d’intégration n’affecte pas l’efficacité globale d’intégration.Enfin, la transcription modifiant la topologie de l’ADN, mon dernier objectif a été d’étudier in vitro l’effet de ce paramètre sur l’intégration. En utilisant des plasmides de différentes formes topologiques comme substrats accepteurs d’intégration, j’ai montré que l’intégration est favorisée sur les formes surenroulées négativement. J’ai également prouvé que cette sélectivité est indépendante de la présence de LEDGF/p75.Mes travaux constituent une étape dans la connaissance des bases moléculaires et mécanistiques de la sélectivité d’intégration du VIH-1 pouvant déboucher sur l’établissement de nouvelles stratégies antirétrovirales. / The integration of the DNA copy of HIV-1 in an infected cell is an essential step of the replication cycle of the retrovirus. It’s performed by a viral enzyme, called integrase, which constitutes a major target of antiviral strategies. Several studies suggest a regulation of integration selectivity by chromatin and transcription. The cellular protein LEDGF/p75, a transcriptional activator, interacting with both integrase and chromatin perfectly illustrates this regulation. My thesis project was to study the links between LEDGF/p75, chromatin and transcription during HIV-1 integration.First, my work validated in vitro the interaction between LEDGF/p75 and its partner TOX4, recently identified by our team. I have also shown that the TOX4 domain, interacting with LEDGF/p75, inhibits integration in vitro on chromatin templates in the presence of LEDGF/p75, suggesting an inhibitory role of TOX4 during the HIV-1 integration step.Then, I developed several in vitro protocols coupling HIV-1 integration and cellular transcription. As RNA polymerase II transcription machinery from Hela nuclear extracts prevents the integration process, I used purified T7 RNA polymerase to perform transcription and studied its consequences on integration. I could show that the synthetized RNA inhibits integration but that the transcription process per se does not affect global integration efficiency on the transcribed template. Since transcription modifies DNA topology, my last goal was to study the effect of this parameter on integration in vitro. Using plasmids of different topological forms as integration acceptor substrates, I showed that integration is enriched in negative supercoiled plasmids. I also proved that this selectivity is independent of the presence of LEDGF/p75. My work constitutes an initial step in understanding the molecular and mechanistic basis of HIV-1 integration selectivity that can lead to the establishment of new antiretroviral strategies.

Page generated in 0.0826 seconds